arrow
K

Kari Kendra

The Ohio State University
H指数:41
被引数:8,358

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signatures

质子泵抑制剂对免疫疗法的影响受先前化疗的调节,并与肠道微生物组–免疫细胞特征相关联

2026-03-090
OAAI
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

可手术切除的增生性黑色素瘤的新辅助PD-1阻滞: SWOG S1512 2期试验的队列A

2026-01-290
OAAI
Cervical Cancer, Version 2.2026

Abu-Rustum, N.R.; Campos, S.M.; Amarnath, S.; Arend, R.; Barber, E.; Bradley, K.; Brooks, R.; Chino, J.; Chon, H.S.; Crispens, M.A. 宫颈癌,版本2.2026,NCCN肿瘤学临床实践指南。J. Natl. Compr. Cancer Netw. 2025, 23, 549–573. [Google Scholar] [CrossRef]

2025-12-010
PRE
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy

Savardekar H, 等人. BRD4抑制可导致MDSC凋亡并增强检查点阻断疗法。临床研究杂志. (2025). doi: 10.1172/JCI181975

2025-10-012
OA
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

早期淋巴细胞/单核细胞比值的变化作为免疫检查点抑制剂治疗晚期癌症患者时预测总生存期的预后标志物

2025-10-010
PRE
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

不可切除的增生性黑色素瘤的Anti-PD-1治疗: SWOG S1512 2期试验

2025-08-140
PRE
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors
2024-11-080
OA
Melanoma: Cutaneous, Version 2.2024 Featured Updates to the NCCN Guidelines
2024-07-018
PRE
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
2024-03-220
PRE
Vulvar Cancer, Version 3.2024
2024-03-0112
OA
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
2023-11-283
OA
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

肺癌患者治疗前胸部影像学检查与免疫检查点抑制剂肺炎的关系

2023-11-015
OA
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
2023-08-1743
OA
S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
2023-04-141
PRE
Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
2023-04-042
PRE
CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616
2023-04-040
PRE